Key Highlights for Investors

• Board Meeting Date: The board will meet on 12 March 2026. The timing of this meeting is important as it signals when shareholders and the market can expect the release of the company’s audited financial performance for 2025.
• Approval and Publication of Annual Results: The annual results for the year ended 31 December 2025 will be reviewed and approved. The release of these results is a potentially price-sensitive event as it will provide investors with key insights into the company’s financial health, operational performance, and any strategic developments that may have occurred during the year.
• Other Business Matters: In addition to the annual results, the Board may also discuss and transact any other business. While the specific topics are not detailed, this leaves room for the announcement of other material developments during or following the Board meeting, which could further impact the company’s share price.
• Board Composition: The Board is currently comprised of:
  • Executive Director: Mr. LU An-Bang (also Chief Executive Officer)
  • Non-Executive Directors: Mr. FU Shan and Mr. CAO Yibo
  • Independent Non-Executive Directors: Dr. YAO Zhengbin (Bing), Mr. CHAN Peng Kuan, Ms. NI Hong, and Mr. ZHANG Qing

  The strong composition of independent directors may enhance transparency and governance in decision-making processes.

Why This Matters for Shareholders

The upcoming Board meeting and subsequent disclosure of the 2025 annual results are highly significant events for shareholders and the market at large. The results will offer a detailed look at the company’s financial and operational performance, which could directly influence investor sentiment and the company’s share price. If the financial results exceed or fall short of market expectations, or if any new strategic initiatives or significant business developments are announced, this could lead to notable share price movements.

What to Watch For

• Timing of Results Release and Market Reaction: Shareholders should closely monitor the company’s announcements around 12 March 2026 for any disclosures related to financial performance, dividends, or other corporate actions.
• Potential for Additional Announcements: As the Board may transact “any other business,” investors should be alert for supplementary disclosures that could impact the valuation or outlook for VISEN Pharmaceuticals.

Disclaimer: This article is prepared for informational purposes only and does not constitute investment advice. Investors should perform their own research or consult with a qualified financial advisor before making investment decisions. All information is based on the company’s public announcement dated 2 March 2026.

View VISEN PHARMA-B Historical chart here